Drug delivery targets and strategies to address mast cell diseases

Clayton H. Rische, Ariel N. Thames, Rebecca A. Krier-Burris, Jeremy A. O’Sullivan, Bruce S. Bochner, Evan A. Scott*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Introduction: Current and developing mast cell therapeutics are reliant on small molecule drugs and biologics, but few are truly selective for mast cells. Most have cellular and disease-specific limitations that require innovation to overcome longstanding challenges to selectively targeting and modulating mast cell behavior. This review is designed to serve as a frame of reference for new approaches that utilize nanotechnology or combine different drugs to increase mast cell selectivity and therapeutic efficacy. Areas covered: Mast cell diseases include allergy and related conditions as well as malignancies. Here, we discuss the targets of existing and developing therapies used to treat these disease pathologies, classifying them into cell surface, intracellular, and extracellular categories. For each target discussed, we discuss drugs that are either the current standard of care, under development, or have indications for potential use. Finally, we discuss how novel technologies and tools can be used to take existing therapeutics to a new level of selectivity and potency against mast cells. Expert opinion: There are many broadly and very few selectively targeted therapeutics for mast cells in allergy and malignant disease. Combining existing targeting strategies with technology like nanoparticles will provide novel platforms to treat mast cell disease more selectively.

Original languageEnglish (US)
Pages (from-to)205-222
Number of pages18
JournalExpert Opinion on Drug Delivery
Issue number2
StatePublished - 2023


  • Mast cells
  • allergy
  • cancer
  • cell targeting
  • mastocytosis
  • nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Drug delivery targets and strategies to address mast cell diseases'. Together they form a unique fingerprint.

Cite this